asxan.ai Agents Hub

Grape Seed Extract

Evidence Fact Sheet

OPC / Proanthocyanidins

Grape seed extract (OPC / oligomeric proanthocyanidins from Vitis vinifera) is a polyphenol-rich botanical studied as an antioxidant and vascular-support ingredient, typically at 150-300 mg/day of standardized (>=95% proanthocyanidin) extract. Meta-analyses report blood-pressure and oxidative-stress-marker effects but several honest null findings. FDA self-affirmed GRAS; EFSA authorized 0 health claims.

Also known as: Grape Seed Extract · GSE · OPC (grape-seed-derived) · Oligomeric Proanthocyanidins · Proanthocyanidins · Vitis vinifera Seed Extract · MegaNatural-BP · Leucoselect · OPC

Overview

Grape seed extract (GSE) is a Vitis vinifera seed-derived botanical standardized to oligomeric proanthocyanidins (OPC), a class of polyphenols studied for free-radical scavenging, endothelial nitric-oxide signaling, NF-kB suppression and inhibition of LDL oxidation in research models. It is most commonly studied in cardiovascular, oxidative-stress and metabolic research contexts, with RCT-validated oral doses of 150-300 mg/day of standardized extract (branded raw materials such as MegaNatural-BP and Leucoselect drove most trials). In the US it is a legal dietary-supplement ingredient with pre-DSHEA Old Dietary Ingredient status and self-affirmed GRAS (FDA no-objection); structure/function claims are permitted with the mandatory disclaimer while disease claims are prohibited. EFSA has authorized 0 health claims, and China NMPA recognizes only an "helps with antioxidation" function for grape-seed OPC. This page reports research findings, not medical advice or a dosing recommendation.

Mechanism of Action

Free-radical scavenging: oligomeric proanthocyanidins (OPC) are potent in-vitro antioxidants that inhibit lipid peroxidation (research-context mechanism; in-vitro ORAC multiples are educational only, not a product property) · Endothelial NO signaling: activation of the eNOS/NO pathway is associated with vasodilation and improved endothelial function in research models · NF-kB suppression: down-regulation of NF-kB-mediated pro-inflammatory signaling (preclinical and biomarker research) · LDL-oxidation inhibition: reduced susceptibility of LDL to oxidation observed in human research (e.g. heavy smokers) · Matrix metalloproteinase (MMP-1/MMP-9) inhibition: dermal collagen/elastin-protective mechanism studied in skin research

Body systems: Cardiovascular · Blood & Hematopoiesis · Cellular Renewal · Skin & Connective Tissue · Vision

Evidence-Based Benefits

Each benefit below is anchored to a specific PubMed-indexed study. Effect sizes, sample sizes, and p-values are reported as published; no values are inferred. Honest negatives and null results are kept alongside the positive findings, and disease-research populations are described as such — Grape Seed Extract is not characterized as a treatment for any disease.

Blood pressure

Meta-analysis supported
  • -6.077 mmHgsystolic · p=0.011
  • -2.803 mmHgdiastolic · p=0.001
  • 16 RCTs / 810trials / participants

In a meta-analysis of 16 randomized controlled trials (810 participants), grape seed extract was associated with statistically significant reductions in both systolic and diastolic blood pressure. The authors noted the effect was more pronounced in younger and obese subjects and in people with metabolic disorders, rather than in healthy normotensives.

Reported effect: SBP WMD = -6.077 mmHg (95% CI -10.736 to -1.419; P=0.011); DBP WMD = -2.803 mmHg (95% CI -4.417 to -1.189; P=0.001), across 16 RCTs / 810 subjects

“Overall analyses found significant reductions for SBP (WMD = -6.077; 95% CI: -10.736 to -1.419; P = 0.011) and DBP (WMD = -2.803; 95% CI: -4.417 to -1.189; P = 0.001) after grape seed extract treatment.”

Source: PMID 27537554 · Zhang 2016 · Medicine (Baltimore)

Oxidative stress & inflammation markers

Meta-analysis supported
  • SMD -1.04malondialdehyde (MDA)
  • SMD -0.44oxidised LDL
  • -0.48 mg/Lhs-CRP

A systematic review and meta-analysis (19 studies in the pooled analysis) found grape seed extract supplementation significantly lowered the lipid-peroxidation marker malondialdehyde, oxidised LDL, and high-sensitivity CRP. The effect on inflammation was selective: standard CRP and white blood cell count were not significantly changed, and the rise in total antioxidant capacity was only marginal.

Reported effect: MDA SMD -1.04 (95% CI -1.65, -0.42); ox-LDL SMD -0.44 (95% CI -0.75, -0.13); hs-CRP WMD -0.48 mg/L (95% CI -0.94, -0.03); CRP and WBC not significant

“GSE supplementation caused a significant decrease in malondialdehyde (SMD: -1.04, 95% CI: -1.65, -0.42), oxidised low-density lipoprotein (SMD: -0.44, 95% CI: -0.75, -0.13) and high-sensitivity C-reactive protein (WMD: -0.48 mg/L, 95% CI: -0.94, -0.03) and a marginally significant increase in total antioxidant capacity (SMD: 0.49, 95% CI: -0.05, 1.04) but did not significantly influence C-reactive protein (WMD: -0.36 mg/L, 95% CI: -1.02, 0.30) and white blood cell count.”

Source: PMID 34107109 · Foshati 2021 · Int J Clin Pract

Cardiovascular risk markers (honest negative)

Null / no benefit Meta-analysis supported
  • -1.54 mmHgsystolic · P=0.02
  • -1.42 bpmheart rate · P=0.01

An earlier meta-analysis of 9 RCTs (390 participants) found grape seed extract significantly lowered systolic blood pressure and heart rate, but reported NO significant effect on diastolic blood pressure, lipid levels, or CRP. This null finding on lipids and CRP is an honest counterpoint to the antioxidant-marker data and shows effects are not uniform across cardiovascular endpoints.

Reported effect: SBP WMD -1.54 mmHg (95% CI -2.85 to -0.22; P=0.02); HR WMD -1.42 bpm (95% CI -2.50 to -0.34; P=0.01); no significant effect on DBP, lipids, or CRP

“grape seed extract significantly lowered systolic blood pressure (weighted mean difference -1.54 mm Hg (95% confidence interval -2.85 to -0.22, P=0.02]) and heart rate (weighted mean difference -1.42 bpm (95% confidence interval -2.50 to -0.34, P=0.01]). No significant effect on diastolic blood pressure, lipid levels, or CRP was found.”

Source: PMID 21802563 · Feringa 2011 · J Am Diet Assoc

Endothelial function / flow-mediated dilation (honest negative)

Null / no benefit Meta-analysis supported
  • -2.20 mmHgdiastolic BP
  • 1.02%FMD · not significant
  • 19 trialscontrolled trials

A meta-analysis of 19 controlled trials found grape seed extract significantly reduced diastolic blood pressure and heart rate, but had NO significant effect on flow-mediated dilation (the direct ultrasound measure of endothelial function) or on systolic blood pressure in this pooled set. Despite the proposed eNOS/NO mechanism, a measurable FMD improvement was not confirmed, with very high heterogeneity (I2 92%).

Reported effect: DBP WMD -2.20 mmHg (95% CI -3.79 to -0.60); HR WMD -1.25 bpm (95% CI -2.32 to -0.19); FMD WMD 1.02% (95% CI -0.62 to 2.66, NS); SBP WMD -3.55 mmHg (95% CI -7.59 to 0.49, NS)

“GSE supplementation significantly reduced DBP (WMD: -2.20 mmHg, 95% CI: -3.79 to -0.60, I2 = 88.8%) and HR (WMD: -1.25 bpm, 95% CI: -2.32 to -0.19, I2 = 59.5%) but had no significant effects on FMD (WMD: 1.02%, 95% CI: -0.62 to 2.66, I2 = 92.0%) and SBP (WMD: -3.55 mmHg, 95% CI: -7.59 to 0.49, I2 = 97.4%).”

Source: PMID 34798267 · Foshati 2022 · Pharmacol Res

Blood lipids / dyslipidaemia

Meta-analysis supported
  • -0.17 mmol/lLDL-cholesterol
  • -0.11 mmol/ltriglycerides
  • 11 RCTs / 536trials / participants

A dose-response meta-analysis of 11 randomized controlled trials (536 participants) found grape seed extract significantly decreased LDL-cholesterol and triglycerides. The effect was modest and selective: there was no significant overall effect on total- or HDL-cholesterol, with reductions appearing mainly at lower doses (<300 mg/day) and shorter interventions (<10 weeks).

Reported effect: LDL-cholesterol -0.17 mmol/l (95% CI -0.34, -0.01); triglycerides -0.11 mmol/l (95% CI -0.18, -0.05); no significant effect on total- or HDL-cholesterol overall

“GSE supplementation significantly decreased serum levels of LDL-cholesterol (-0·17 mmol/l; 95 % CI -0·34, -0·01) and TAG (-0·11 mmol/l; 95 % CI -0·18, -0·05).”

Source: PMID 32138795 · Anjom-Shoae 2020 · Br J Nutr

Dosage (research context · not a recommendation)

RCT-validated oral doses are 150-300 mg/day of standardized extract (>=95% proanthocyanidins); MegaNatural-BP 300 mg/day is the most-validated blood-pressure dose, and lipid/metabolic trials extend to ~400 mg/day. No formal Upper Limit established. Branded raw materials (MegaNatural-BP, Leucoselect) drove most trials, so efficacy extrapolation to generic GSE warrants caution. Educational reference, not a dosing recommendation.

Regulatory Status · 4 Markets

US · FDA
Legal dietary-supplement ingredient: pre-DSHEA Old Dietary Ingredient and self-affirmed GRAS (FDA no-objection). DSHEA structure/function claims (e.g. antioxidant support, supports healthy blood pressure already within the normal range) permitted with the mandatory FDA disclaimer; disease claims prohibited. No FDA-authorized health claim.
EU · EFSA
Marketable as a food-supplement ingredient (long history of use, not a Novel Food); traditional-herbal (THR) registrations exist in France/Italy for venous function. EFSA has authorized 0 health claims — antioxidant and cardiovascular Article 13 claims (incl. proanthocyanidins ID 1334) were rejected for insufficient evidence.
BR · ANVISA
Brazil ANVISA: legal botanical food-supplement ingredient under RDC 240/2018; claims must follow ANVISA-recognized wording; no single-ingredient authorized functional claim. [China NMPA: listed health-food raw material; multiple OPC blue-hat health foods approved for the authorized function 'helps with antioxidation' — the only function approved for grape-seed OPC in China; also a conventional-food ingredient per GB/T 22250-2008.]

Safety

Excellent tolerability — across RCTs adverse-event rates were not significantly different from placebo; rare mild headache, dizziness or nausea. FDA self-affirmed GRAS with no-objection notices. OPC has mild antiplatelet activity (Shenoy 2007), so people taking anticoagulants/antiplatelets (warfarin, aspirin) should consult a professional, and discontinuation ~2 weeks before surgery is commonly advised. A controlled trial found no clinically significant effect on CYP2D6-substrate pharmacokinetics (Goey 2013, dextromethorphan probe). Safety data in pregnancy/lactation are insufficient; people with grape allergy should avoid it. This page describes scientific evidence, not medical advice; people treated for hypertension or on blood thinners should not self-substitute it for medical care.

References

PubMed-indexed citations anchoring the benefit findings above. Effect sizes are reported as published.

  1. PMID 27537554 · Zhang 2016 · Medicine (Baltimore) — Blood pressure
  2. PMID 34107109 · Foshati 2021 · Int J Clin Pract — Oxidative stress & inflammation markers
  3. PMID 21802563 · Feringa 2011 · J Am Diet Assoc — Cardiovascular risk markers (honest negative)
  4. PMID 34798267 · Foshati 2022 · Pharmacol Res — Endothelial function / flow-mediated dilation (honest negative)
  5. PMID 32138795 · Anjom-Shoae 2020 · Br J Nutr — Blood lipids / dyslipidaemia

Frequently Asked Questions

1. What is grape seed extract and what is OPC?

Grape seed extract (GSE) is a polyphenol-rich botanical made from the seeds of Vitis vinifera and standardized to oligomeric proanthocyanidins (OPC), the active class also called proanthocyanidins. In research models OPCs act as free-radical scavengers, inhibit LDL oxidation, and modulate the eNOS/NO and NF-kB pathways. RCT-validated oral doses are 150-300 mg/day of standardized (>=95% proanthocyanidin) extract; branded raw materials such as MegaNatural-BP and Leucoselect drove most trials, so extrapolating to generic GSE warrants caution.

2. What does the strongest evidence show for blood pressure?

A meta-analysis of 16 randomized controlled trials (810 participants) reported significant reductions in systolic (-6.077 mmHg) and diastolic (-2.803 mmHg) blood pressure (Zhang 2016, PMID 27537554). An earlier 9-RCT meta-analysis (390 participants) also found a smaller systolic reduction (-1.54 mmHg) but no significant effect on diastolic pressure (Feringa 2011, PMID 21802563), so the magnitude varies by trial set and population. These are research findings in studied populations, not a treatment for high blood pressure.

3. Are there honest negative findings I should know about?

Yes. The 9-RCT cardiovascular meta-analysis found NO significant effect on diastolic blood pressure, lipid levels, or CRP (Feringa 2011, PMID 21802563). A 19-trial meta-analysis found no significant effect on flow-mediated dilation, the direct measure of endothelial function (Foshati 2022, PMID 34798267). And the oxidative-stress meta-analysis found standard CRP and white blood cell count were not significantly changed even though malondialdehyde and oxidised LDL fell (Foshati 2021, PMID 34107109). Effects are selective, not uniform across every cardiovascular endpoint.

4. How is grape seed extract regulated and is it safe?

In the US, GSE is a legal dietary-supplement ingredient with pre-DSHEA Old Dietary Ingredient status and self-affirmed GRAS (FDA no-objection); structure/function claims are allowed with the mandatory disclaimer, but disease claims are prohibited. EFSA has authorized 0 health claims, and China's NMPA recognizes only an antioxidation function for grape-seed OPC. Across RCTs, adverse-event rates were not significantly different from placebo (rare mild headache, dizziness or nausea). Because OPC has mild antiplatelet activity, people on anticoagulants/antiplatelets or approaching surgery, and those with grape allergy or in pregnancy/lactation, should consult a professional. This page reports evidence, not medical advice.

Last evidence review: 2026-06-27

← Evidence library

Ask Agent Axor